Probiotics Industry Says FDA Regulatory Bar Is Set Too High
This article was originally published in The Tan Sheet
Research on probiotics’ health benefits rapidly grows, but turning studies into label claims lags due to differences between industry, NIH and FDA about standards for claims substantiation. Attendees at a U.S. Pharmacopeia conference outline the challenges to finding common ground
You may also be interested in...
In the wake of FDA’s draft guidance on NDI notifications, more companies reevaluate the status of their ingredients before going to market. The GRAS for use in foods process is a clear – but rigorous – alternative pathway.
Present and former top FDA officials with oversight of dietary supplements defend the draft guidance on new dietary ingredient notifications, saying the document serves important public health priorities and will not be onerous to industry.
Worldwide consumer health sales in January-March period were down 3.3% to $3.5bn with results off 7.4% to $1.6bn in the US and up 0.5% to $1.9bn internationally. However, excluding “COVID-19 comparison” in the year-ago period, the consumer health segment grew low-single-digits.